There were 2 main objectives: 1. To compare the procedural efficacy of CBG1 and CBG2 by analyzing rates of acute PVI, time to isolation (TTI), balloon
C atheter ablation is more effective than antiarrhythmic drug treatment for patients with symptomatic atrial fibrillation (AF), 1, 2 and pulmonary vein isolation (PVI) is the main target of AF ablation. [3] [4] [5] Cryoballoon (CB) ablation is a safe and effective option to achieve permanent PVI and freedom from AF. [6] [7] [8] [9] Clinical Perspective on p 299
The optimal freezing zone of first CB (CBG1) is around the equator of the balloon. Positioning of CBG1 with a coaxial orientation at the ostium of the PV is important to create circumferential lesions. Especially for inferior veins, this is often challenging with CBG1.
The second generation of the CB (CBG2), Arctic Front Advance (Medtronic, Inc., Minneapolis, MN), was approved by the Food and Drug Administration in 2012. It provides a more uniform and distal cooling. This permits balloon angulations for challenging PV anatomy without leaving the optimal freezing zone. The number of refrigerant jets on the injection coil has been increased from 4 to 8. The flow rate of liquid N 2 O in the inner injection tube was increased by 16% for the 28-mm CBG2 (information provided by Medtronic GmbH, Meerbusch, Germany). Results of a preclinical animal study with 10 dogs are suggestive of equal safety and higher efficacy in lesion generation. 10 Human clinical studies are sparse. Two different centers published their initial experience in roughly 100 patients treated with CBG2 until now. [11] [12] [13] Because of the expected higher efficacy of CBG2, data comparing both CB generations are important to determine the potential benefits and risks.
Study Population
From 2007 to November 2012, all patients undergoing CB ablation for catheter ablation of symptomatic AF at our center were prospectively enrolled in a consecutive fashion. Informed consent was obtained from all patients for the observational registry study which was approved by the local ethical committee. Baseline characteristics, periprocedural data, and follow-up during blanking period for procedure-associated complications were assessed prospectively. For this interim analysis, we included only patients undergoing a CB procedure in combination with the Achieve spiral mapping catheter (Medtronic Inc., Minneapolis, MN) introduced in March 2011 as the standard catheter to our laboratory for positioning of the balloon and real-time PV potential recordings. Until May 2012, all patients were treated with the Arctic Front, and afterward, all patients were treated with the Arctic Front Advance.
Ablation Procedure and Verification of PVI
CB procedure was performed with an anatomy-based individualized approach as described before using 23-or 28-mm or both balloons (CBG1: Arctic Front and CBG2: Arctic Front Advance, Medtronic Inc., Minneapolis, MN). 9, 14 Detailed information is provided in the Appendix in the Data Supplement. In a subgroup of patients, an ET probe (SensiTherm, St. Jude Medical, Saint Paul, MN) was used. Standard freezing time was 300 seconds for the CBG1 and 240 seconds for CBG2. Early PV reconduction was defined as any recurrence of PV entrance signals or demonstration of exit conduction after isolating the target vein until the end of the procedure. 
AF Recurrence Until Discharge
After the procedure, patients were continuously monitored with ECG on intermediate intensive care unit until the next day. At least one 24-hour Holter ECG and additional ECGs in case of symptoms were performed before the scheduled discharge at day 3 after the procedure.
Statistical Analysis
Categorical variables are expressed as numbers and percentages. Continuous variables are expressed as means with SD or as estimated marginal means with SE. For comparison of data between both groups, the χ 2 test or Fisher exact test was used for categorical variables. The Mann-Whitney-Wilcoxon test or 2-sided Student t test for continuous variables was used if applicable after testing for normal distribution using the Shapiro-Wilk test. The generalized estimating equation approach was used to account for within-subject correlation among repeated measures using an AR (1) (autoregressive-type 1 working correlation structure) working correlation structure and robust (sandwich) covariance estimators for the regression coefficients. Predictors included in each model in addition to the intercept were the main effects (see below). To maintain the family-wise error rate associated with testing multiple outcomes, we used the sequential step-down rejective Bonferroni adjustment for the analysis. All P values were calculated by 2-tailed tests. Statistical significance was defined at P<0.05. Data processing and analysis was performed by Excel 2010 (Microsoft Corp., Redmond, WA) and SPSS 21.0 (IBM Corp., Armonk, NY).
Results
From 2007 to November 2012, in total 684 patients with paroxysmal (422/684 [62%]) or persistent AF (262/684 [38%]) underwent CB ablation procedures at our center. A total of 808 CB procedures were performed in 684 patients (1.18 procedures per patient). In 484 of 684 (71%) patients, the Achieve spiral mapping catheter was used as the standard catheter for positioning of the balloon and PV potential recording. All of them were included in the present analysis. Three hundred sixty-four of 484 (75%) procedures were performed with CBG1 and 120 of 484 (25%) with CBG2.
Baseline characteristics are shown in Table 1 . In the CBG2 group, more patients had persistent AF (42% versus 47.5%; P=0.032), and no significant difference was found for age, female sex, LA diameter, and structural heart disease. At baseline, more patients in CBG2 were treated with antiarrhythmic drugs (27% versus 59%; P=0.0001). ET measurement was used in 52 of 364 (14%) patients treated with CBG1 and 101 of 120 (84%) patients treated with CBG2.
Procedural Data and Acute Success Rates
Acute PVI with CB was achieved in 99.86% and 100% of veins with CBG1 and CBG2, respectively (P=0.43; Table 2 ). We found a trend toward a lower total number of cryo applications per patient (12.1±3.3 versus 11.6±2.5; P=0.06), a significant lower number of applications per vein (2.98±1.2 versus 2.82±1.1; P=0.007), and a lower number of freezes until PVI was achieved for each vein (1.45±0.81 versus 1.28±0.64; P=0.001) with CBG2. The need for a second balloon decreased significantly with CBG2 (58% versus 21%; P=0.0001). Focal touch-up applications to achieve PVI were necessary in 2 of 1471 (0.14%) of veins treated with CBG1 and 0 of 476 (0%) of veins treated with CBG2 (P=1.0). A significant reduction of fluoroscopy time (34±12 versus 29±11 minutes; −15%; P<0.001), LA dwell time (139±40 versus 124±39 minutes; −11%; P<0.001), and total procedure time (185±49 versus 175±45; −5%; P=0.038) was found.
Feasibility of Real-Time PV Potential Recordings
Real-time PV potential recordings during cryo application for assessment of TTI was feasible in 456 of 1471 of veins (31%) when using CBG1 and in 208 of 476 of veins (44%) using CBG2 (P<0.001) ( Table 3 ). Comparing the feasibility to assess TTI for each of the different PVs, we found significantly higher rates of PV potential recordings for left inferior PV, right inferior PV, and right superior PV (P<0.01) and a nonsignificant trend for left superior PV for CBG2 ( Figure) .
Time to Isolation
Within the generalized estimating equation model (Table 3) , CB generation group and CB size were both a significant factor for TTI. However, the 2-way interaction of group and size did not reach statistical significance. TTI was significantly shorter with CBG2 compared with CBG1 and for 23-mm compared with 28-mm balloon ( Table 4 ). With CBG1, we found early PV reconduction in 38 of 1471 of veins and only in 2 of 476 of veins with CBG2 (2.6% versus 0.42%; P=0.0023).
Recurrence of AF Until Discharge
In the CBG1 group, 55 of 364 (15.1%) and in the CBG2 group 18 of 120 (15.0%) patients had documented early AF recurrences until discharge (P=1.0). 
Balloon Temperature
Within the generalized estimating equation model (Table 3) for BT, we found significant main effects of the factors CB size, the 2-way interactions CB generation (group) and size, as well as group and inferior versus superior PV. The 2-way interaction between group and right versus left PV did not reach the level of significance. We found a significant 4-way interaction of group, size, inferior versus superior, and right versus left (P=0.003). Subsequent pairwise comparison (Table 4 ) reveals significant warmer BT for 23-mm CBG2 and a nonsignificant trend to colder BT for 28-mm CBG2 when compared with its predecessor. If each PV is analyzed separately, these findings could be confirmed for left superior PV and left inferior PV with 23-mm CBG2: For both veins, the BT were warmer compared with CBG1 (Table 4 ).
Cryo application interruptions because of low BT (<−60°C when ablating right superior PV) were rarely documented with CBG1: 6 of 364 (1.65%) with a nonsignificant trend to a higher abortion rate with CBG2 (4/120 [3.33%]; P=0.27).
Esophageal Temperatures
Within the generalized estimating equation model (Table 3) , no significant effect of the factor CB generation group on ET was found. In contrast, the factors balloon size, inferior versus superior, and right versus left have a significant impact on ET. The highly significant 4-way interaction of group, size, inferior versus superior, and right versus left PV indicates that with both CB generations there is a trend for colder ET for the left-sided and inferior veins (see Appendix in the Data Supplement for bar chart figure) . The number of freeze abortions attributable to low ET were similar: CBG1, 8 of 52 (15.4%) versus 17 of 101 (16.8%); P=0.82. The lowest ET was −1°C and occurred during ablation at the ostium of left inferior PV after 235 seconds with the 28-mm CBG1. The lowest ET with 28-mm CBG2 was 6.8°C. The lowest ET with the 23-mm size was 9.9°C for CBG1 and 12.1°C for CBG2.
Phrenic Nerve Palsy
Transient phrenic nerve attenuation during the procedure requiring abortion of the freeze but with documented phrenic nerve function before discharge was observed in 75 of 364 (20.6%) with CBG1 and 33 of 120 (27.5%) with CBG2 (P=0.12). Persistent right phrenic nerve palsy (PNP) defined as PNP which was not resolved until discharge and persistent until the last documented follow-up visit was observed in 4 of 364 (1.1%) patients treated with the CBG1 and 2 of 120 (1.7%) patients treated with CBG2 (P=0.64).
Adverse Events
For >90% of patients in both groups, an additional follow-up for complications ≥30 days was available ( Table 5 ). In both groups, a major adverse event rate of 3.3% was observed (P=not significant) including PNP. One minor stroke was observed with CBG1, which was resolved after 6 months. One gastroparesis was observed after CB ablation with 23-mm CBG1. Gastric drainage and parenteral nutrition was necessary during the first week after CB ablation. Afterward, the patient was treated conservatively. One year later, occasional eructation persisted.
Discussion
With either CBG1 or CBG2, a high rate of PVI can be achieved (99.86% versus 100%; P=0.43) without additional radiofrequency or cryo-tip catheter touch-up ablations although standard freezing time was reduced from 300 to 240 seconds for CBG2. The need for 2 different balloon sizes decreased when using CBG2 and significantly shorter procedure, LA, and fluoroscopy times demonstrate that with CBG2 PVI became a less complex procedure. LA dwell time, less influenced by other factors compared with total procedure time (eg, laboratory logistics), decreased by a mean of 15 minutes. We found a significant increase in efficacy for CBG2 with a lower number of applications until PVI was achieved and a significant reduction of TTI especially with 28-mm CBG2, which was modified by an increased refrigerant flow. Moreover, we rarely found early reconduction during the procedure with the CBG2 (0.42%), whereas there was an incidence of early reconduction with the CBG1 of 2.6% (P=0.0023). Other authors found early reconduction in 2.9% for CBG1. 15 Recently, we have published data on predictors for intraprocedural reconduction using the first CB generation. 9 The cutoff TTI for predicting a stable PVI was 83 seconds. A new predictive cutoff TTI for procedural success with CBG2 cannot be calculated because of the low number of reconducting veins with CBG2. With CBG1 Vogt et al 8 published a PVI rate of 91.1% of patients with CB only, using the smaller balloon in 26.7%, the larger balloon in 25.6%, and both balloons in 47.7% of patients. Other authors prefer to use the 28-mm CB only and achieve PVI in 98% of veins with CBG2. 16 Our strategy is an anatomically based method with previous LA/PV imaging using the 28-, 23-mm, or both balloons. During the procedure, we used a 3-dimensional reconstruction of the LA to visualize the anatomic variants and to facilitate probing different branches. Although double balloon rate decreased significantly, even with the CBG2 one third of the procedures were still performed with 23-mm CB only and additional 21% of patients were treated with 23-plus 28-mm CBG2 (see Movies in the Data Supplement).Whether our results can be confirmed by others, for example, with the single big balloon strategy, remains to be demonstrated. Of course, one may argue that in the CBG2 group patients were treated more often with antiarrhythmic drugs and persistent AF was more often present in the CBG2 group at baseline. Long-term outcome of antiarrhythmic drugs is important to determine whether the enhanced procedural performance of CBG2 results in a potential clinical benefit. Surprisingly, 23-mm CBG2 showed a slight increase in BT, but we observed a higher efficacy represented by a lower TTI for the 23-mm CBG2. This might be explained by the more distal and more uniform cooling zone with a nonmodified position of the temperature electrode proximal in the balloon and an unchanged refrigerant flow leading to measurements of slightly higher BTs but lower TTIs. In contrast, with 28-mm CBG2, a slight decrease of the BT was observed. This finding can be attributed to the increase of the refrigerant flow for 28-mm CBG2. Our results are in accordance with the recently described broader lesion sets demonstrated in animal studies for CBG2. 10 Nonsignificant trends for increased rates of transient and persistent PNP were observed with CBG2 compared to CBG1. With CBG2, we used more consistently an empirically determined cutoff criterion of −60°C BT when ablating the right superior PV. This might have had an influence on the rates of PNP in our study.
The feasibility of balloon positioning plus real-time PV potential recordings with the spiral mapping catheter Achieve (Medtronic, Inc.) revealed an improvement when using the catheter together with CBG2 (31% versus 44%; P<0.001). This result may be attributable to the improved cooling zone allowing noncoaxial positions of the balloon at the PV ostium featuring easier contact to the venous wall with the spiral mapping catheter. Nevertheless, rates of TTI are still low. Chierchia et al 17 published a higher TTI feasibility rate of 55% with the 20-mm Achieve catheter and achieved PVI in 94% of veins. Our main focus is the perfect occlusion, therefore we mostly use the 15-mm Achieve catheter, which gives us a better support for positioning and might be inferior in TTI determination.
Comparing the major adverse event rates for CBG1 (3.30%) and CBG2 (3.33%), we did not find significant differences (P=1.0). Thus, CBG2 seems to be as safe as CBG1. For radiofrequency ablation, a major adverse event rate of 4.5% has been published. 18 In our study, the major adverse event rate was significantly lower for both of the CB generations.
Esophageal lesions have been reported for CBG2 in up to 19% of cases. 12, 13 Although we do not have data on esophageal lesions, we found no significant differences for CBG1 and CBG2 when analyzing minimal ET or the abortion rate because of low ET +15°C. These findings might be biased because in the CBG2 group we used ET probes more often (14% versus 84%). One patient from the CBG1 group had reflux symptoms because of an esophageal lesion which resolved without sequela. In our laboratory, we stopped cryo application if an ET ≤+15°C is observed.
Data from the ongoing prospective, multicenter, multinational comparative FREEZE Cohort Study (ClinicalTrials.gov identifier: NCT01360008) may help to optimize the procedure in the future and will compare radiofrequency and CB ablation in a real-world scenario with 2000 patients in each group.
Limitations
A major limitation of our study is the observational single-center design. Because the study is historically controlled, a learning curve might bias the results. But, before March 2011, we have already performed >200 CB procedures in our laboratory. Therefore, the impact of the learning curve to the current analysis is expected to be low. The difference in group sizes might further bias the results. Because it was a nonrandomized trial with an individualized strategy, balloon use differs significantly between the groups. At that point of time, we cannot provide long-term follow-up for both groups, which would allow comparison of clinical efficacy in the long run. At least, we provide a posthospital follow-up for complications ≥30 days.
Conclusions
Our results demonstrate high rates of acute PVI with significant enhancements to key procedural metrics, though not at the cost of complications or procedure complexity. The CBG2 is safe and effective for PVI in the treatment of AF. More data are necessary to establish procedural safety limits. A comparison of long-term safety and efficacy data for both balloon generations is required. 
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CLINICAL PERSPECTIVE
Cryoballoon ablation became a frequently used technique for pulmonary vein isolation in patients with symptomatic atrial fibrillation. With the second-generation cryoballoon, the procedure became faster and less complex because of several enhancements of the system. The present article gives an overview of the improvements of the cryoballoon and demonstrates the significant impact on procedural efficacy in a high-volume single center. Interventional electrophysiologists new to cryoballoon ablation can learn from the detailed procedural data and understand the parameter's dimensions such as balloon and esophageal temperatures as well as the time to isolation. Evidence is provided for a much faster lesion generation without affecting the safety profile. Cryoballoon user can find out how experts set their individual safety limits to ensure the low complication rate with a new ablation tool and how they manage difficult anatomies with an individualized anatomic approach to achieve pulmonary vein isolation in almost 100% of veins with the balloon only.
